DK0553178T3 - Bifasiske afgivelsesformuleringer til lipofile lægemidler - Google Patents

Bifasiske afgivelsesformuleringer til lipofile lægemidler

Info

Publication number
DK0553178T3
DK0553178T3 DK91918238.6T DK91918238T DK0553178T3 DK 0553178 T3 DK0553178 T3 DK 0553178T3 DK 91918238 T DK91918238 T DK 91918238T DK 0553178 T3 DK0553178 T3 DK 0553178T3
Authority
DK
Denmark
Prior art keywords
pct
active substance
fatty acid
date
pharmaceutically active
Prior art date
Application number
DK91918238.6T
Other languages
Danish (da)
English (en)
Inventor
Stephen George Barnwell
Original Assignee
Cortecs Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cortecs Ltd filed Critical Cortecs Ltd
Application granted granted Critical
Publication of DK0553178T3 publication Critical patent/DK0553178T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Vehicle Interior And Exterior Ornaments, Soundproofing, And Insulation (AREA)
  • Professional, Industrial, Or Sporting Protective Garments (AREA)
  • Laminated Bodies (AREA)
  • Materials For Medical Uses (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK91918238.6T 1990-10-19 1991-10-18 Bifasiske afgivelsesformuleringer til lipofile lægemidler DK0553178T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909022788A GB9022788D0 (en) 1990-10-19 1990-10-19 Pharmaceutical formulations

Publications (1)

Publication Number Publication Date
DK0553178T3 true DK0553178T3 (da) 1995-07-24

Family

ID=10684032

Family Applications (1)

Application Number Title Priority Date Filing Date
DK91918238.6T DK0553178T3 (da) 1990-10-19 1991-10-18 Bifasiske afgivelsesformuleringer til lipofile lægemidler

Country Status (21)

Country Link
US (1) US5391377A (fr)
EP (1) EP0553178B1 (fr)
JP (1) JP3276368B2 (fr)
KR (1) KR100188642B1 (fr)
AT (1) ATE122881T1 (fr)
AU (1) AU656924B2 (fr)
BG (1) BG61383B1 (fr)
CA (1) CA2093206C (fr)
CZ (1) CZ282822B6 (fr)
DE (1) DE69110052T2 (fr)
DK (1) DK0553178T3 (fr)
ES (1) ES2073177T3 (fr)
FI (1) FI104408B (fr)
GB (1) GB9022788D0 (fr)
HK (1) HK85296A (fr)
HU (2) HUT64215A (fr)
NO (1) NO305505B1 (fr)
RO (1) RO114739B1 (fr)
RU (1) RU2121344C1 (fr)
SK (1) SK279845B6 (fr)
WO (1) WO1992006680A1 (fr)

Families Citing this family (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5662933A (en) * 1993-09-09 1997-09-02 Edward Mendell Co., Inc. Controlled release formulation (albuterol)
US5455046A (en) * 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5773025A (en) 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
GB9325445D0 (en) * 1993-12-13 1994-02-16 Cortecs Ltd Pharmaceutical formulations
US5567592A (en) * 1994-02-02 1996-10-22 Regents Of The University Of California Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
US5430021A (en) * 1994-03-18 1995-07-04 Pharmavene, Inc. Hydrophobic drug delivery systems
DE4443175A1 (de) * 1994-12-05 1996-06-13 Jenapharm Gmbh Neue pulsatile Arzneiform
US5834024A (en) 1995-01-05 1998-11-10 Fh Faulding & Co. Limited Controlled absorption diltiazem pharmaceutical formulation
ES2154806T3 (es) * 1995-02-06 2001-04-16 Elan Pharma Int Ltd Formulaciones de compuestos como dispersiones de nanoparticulas en aceites o acidos grasos digeribles.
US5716928A (en) * 1995-06-07 1998-02-10 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
US5665386A (en) * 1995-06-07 1997-09-09 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
JPH11507356A (ja) * 1995-06-07 1999-06-29 アブマックス，インコーポレイティド 経口薬理化合物の生物有用性を高めるためのエッセンシャルオイルの利用
US6024980A (en) * 1996-06-28 2000-02-15 Mcneil-Ppc, Inc. Multiphase soft gelatin dosage form
WO1998001117A1 (fr) 1996-07-08 1998-01-15 Edward Mendell Co., Inc. Matrice a liberation prolongee pour medicaments insolubles en doses elevees
US6458373B1 (en) * 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US6056977A (en) * 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
US20030008919A1 (en) * 1999-06-03 2003-01-09 Jean-Baptiste Roullet Use of retinoids to treat high blood pressure and other cardiovascular disease
JP2002500190A (ja) 1998-01-08 2002-01-08 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 海洋海綿から誘導されるキネシンモーターモジュレーター
US7030155B2 (en) * 1998-06-05 2006-04-18 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US6524620B2 (en) 1998-07-20 2003-02-25 Andrx Pharmaceuticals, Inc. Diltiazem controlled release formulation and method of manufacture
US6200968B1 (en) * 1998-08-06 2001-03-13 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles
FR2782006B1 (fr) * 1998-08-07 2002-04-19 Gattefosse Ets Sa Composition a liberation prolongee apte a former une micro-emulsion
PL348193A1 (en) 1998-12-11 2002-05-06 Pharmasolutions Self-emulsifying compositions for drugs poorly soluble in water
US6057289A (en) * 1999-04-30 2000-05-02 Pharmasolutions, Inc. Pharmaceutical composition comprising cyclosporin in association with a carrier in a self-emulsifying drug delivery system
CA2409437A1 (fr) * 2000-05-11 2001-11-22 Pharmacia Corporation Composition antagoniste de l'aldosterone destinee a etre liberee durant l'acrophase de l'aldosterone
US6664230B1 (en) 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US8568766B2 (en) * 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
CA2480826C (fr) * 2002-04-09 2012-02-07 Flamel Technologies Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee de principe(s) actif(s)
US7670612B2 (en) 2002-04-10 2010-03-02 Innercap Technologies, Inc. Multi-phase, multi-compartment capsular delivery apparatus and methods for using same
US20040005359A1 (en) * 2002-06-27 2004-01-08 Cheng Xiu Xiu Controlled release oral dosage form
US20040077621A1 (en) * 2002-08-08 2004-04-22 Academia Sinica Antioxidants
CA2515544A1 (fr) * 2003-02-11 2004-08-26 Kemia Inc. Composes destines au traitement d'une infection virale
US7314640B2 (en) * 2003-07-11 2008-01-01 Mongkol Sriwongjanya Formulation and process for drug loaded cores
KR20060123551A (ko) * 2004-01-14 2006-12-01 라비팜 라보라토리즈, 인크. 최소한 한 개의 지방산을 포함하는 디하이드로피리딘 타입칼슘 길항제용 경피 전달 장치
MXPA06009054A (es) * 2004-02-11 2007-04-16 Athpharma Ltd Composiciones cronoterapeuticas y metodos de su uso.
US8741635B2 (en) 2004-05-12 2014-06-03 The Walter And Eliza Hall Institute Of Medical Research Method of cell isolation
WO2006095347A2 (fr) 2005-03-10 2006-09-14 Ben Gurion University Of The Negev Research And Development Authority Ltd. Preparations de vdac1 et leurs methodes d'utilisation pour reguler l'apoptose
US8648045B2 (en) 2005-03-10 2014-02-11 Ben Gurion University Of The Negev Research And Development Authority Ltd. VDAC1 compositions and methods of use thereof for regulating apoptosis
EP1890715A4 (fr) 2005-04-29 2009-10-28 Univ California Peptides et mimetiques de peptides destines a traiter les pathologies caracterisees par une reaction inflammatoire
WO2006135985A1 (fr) 2005-06-24 2006-12-28 The Walter And Eliza Hall Institute Of Medical Research Molécules thérapeutiques pro-apoptotiques similaires à bh3 et procédés de génération et/ou de sélection desdites molécules
US8691272B2 (en) * 2005-12-30 2014-04-08 Intelgenx Corp. Multilayer tablet
AU2007207341B2 (en) 2006-01-20 2012-05-10 Women's & Children's Health Research Institute Incorporated Method of treatment, prophylaxis and diagnosis of pathologies of the bone
US8440788B2 (en) * 2006-04-06 2013-05-14 Ben-Gurion University Of The Negev Research And Development Authority Ltd. N-terminal VDAC variants and uses thereof
WO2007123153A1 (fr) * 2006-04-19 2007-11-01 Ono Pharmaceutical Co., Ltd. Capsule pour administration orale
MY153288A (en) * 2006-06-28 2015-01-29 Hovid Berhad An effective pharmaceutical carrier for poorly bioavailable drugs
KR101390695B1 (ko) * 2006-08-01 2014-04-30 오츠카 세이야쿠 가부시키가이샤 약리 활성 물질의 흡수성이 개선된 의약 조성물
EP2086512A2 (fr) * 2006-10-27 2009-08-12 Janssen Pharmaceutica N.V. Compositions pharmaceutiques granulaires sèches et leurs procédés de production
CA2691539C (fr) * 2007-06-21 2014-08-26 Angelica Therapeutics, Inc. Toxines modifiees
ES2402334T3 (es) 2007-08-02 2013-04-30 Gilead Biologics, Inc Procedimientos y composiciones para el tratamiento y el diagnóstico de la fibrosis
WO2009032693A2 (fr) * 2007-08-28 2009-03-12 Uab Research Foundation Polypeptides de synthèse imitant l'apolipoprotéine e et leurs procédés d'utilisation
US8557767B2 (en) 2007-08-28 2013-10-15 Uab Research Foundation Synthetic apolipoprotein E mimicking polypeptides and methods of use
EP2205245B1 (fr) * 2007-10-03 2015-06-24 WisTa Laboratories Ltd. Utilisation thérapeutique de diaminophénothiazines
WO2009110944A1 (fr) 2008-02-29 2009-09-11 Angelica Therapeutics, Inc. Toxines modifiées
ES2390562T3 (es) * 2008-05-12 2012-11-14 Capsugel Belgium Nv Cápsula mejorada con aberturas para el aire
US20100082438A1 (en) * 2008-10-01 2010-04-01 Ronnie Jack Garmon Methods and systems for customer performance scoring
US9050276B2 (en) 2009-06-16 2015-06-09 The Trustees Of Columbia University In The City Of New York Autism-associated biomarkers and uses thereof
EP2722055A1 (fr) 2009-08-17 2014-04-23 Tracon Pharmaceuticals, Inc. Therapie combinatoire avec anticorps et des agents anti-VEGF pour le traitement du cancer
US8221753B2 (en) 2009-09-30 2012-07-17 Tracon Pharmaceuticals, Inc. Endoglin antibodies
ES2363965B1 (es) * 2009-11-20 2013-01-24 Gp Pharm S.A. Cápsulas de principios activos betabloqueantes y ésteres de ácidos grasos poliinsaturados.
US10610528B2 (en) 2009-12-08 2020-04-07 Intelgenx Corp. Solid oral film dosage forms and methods for making same
US20110136815A1 (en) * 2009-12-08 2011-06-09 Horst Zerbe Solid oral film dosage forms and methods for making same
US9249189B2 (en) 2010-01-18 2016-02-02 Albany Medical College Alpha-fetoprotein “ring and tail” peptides
PL2608809T3 (pl) 2010-08-27 2019-10-31 Gilead Biologics Inc Przeciwciała dla metaloproteinazy 9 macierzy
CN108404115A (zh) 2010-10-15 2018-08-17 纽约市哥伦比亚大学理事会 肥胖症-相关的基因和它们的蛋白和其用途
AU2012249301A1 (en) 2011-04-29 2013-11-21 Kinemed, Inc. Chemical modification of apolipoprotein mimetic peptides for the production of therapeutic agents
CN103957888B (zh) * 2011-09-29 2017-11-21 PLx 制药公司 用于将药物沿胃肠道靶向释放的pH依赖性载体、其组合物及其制备和应用
US9550836B2 (en) 2012-02-29 2017-01-24 Gilead Biologics, Inc. Method of detecting human matrix metalloproteinase 9 using antibodies
CN104271156B (zh) 2012-02-29 2017-06-16 吉利德生物制剂公司 抗基质金属蛋白酶9的抗体
US20150011471A1 (en) 2012-03-01 2015-01-08 Yeda Research And Development Co. Ltd. Regeneration of islet beta cells by hsp60 derived peptides
US10039777B2 (en) 2012-03-20 2018-08-07 Neuro-Lm Sas Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders
TW201406707A (zh) 2012-05-04 2014-02-16 Acucela Inc 用以治療糖尿病性視網膜病變及其他眼部疾病之方法
EP2874647B1 (fr) 2012-07-20 2018-10-24 La Trobe University Procédé de diagnostic et de traitement de cancer metastasique
UA115789C2 (uk) 2012-09-05 2017-12-26 Трейкон Фармасутікалз, Інк. Композиція антитіла до cd105 та її застосування
NZ713291A (en) 2013-03-14 2017-04-28 Uab Res Found Apolipoprotein mimetics and uses thereof
CA2902905A1 (fr) 2013-03-15 2014-09-25 Claude Geoffrey Davis Toxines modifiees
EP2968503B1 (fr) 2013-03-15 2018-08-15 Intrinsic LifeSciences LLC Anticorps antihepcidine et leurs utilisations
CA2902209A1 (fr) 2013-03-15 2014-09-18 The Regents Of The University Of California Peptides a toxicite reduite stimulant un ecoulement de cholesterol
US9758559B2 (en) 2013-07-25 2017-09-12 B.G. Negev Technologies And Applications Ltd., At Ben-Gurion University Short peptides derived from VDAC1, compositions and methods of use thereof
US9873724B2 (en) 2013-12-20 2018-01-23 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Pro-angiogenic peptides and peptide conjugates
CA2940869A1 (fr) 2014-02-27 2015-09-03 Gilead Sciences, Inc. Anticorps diriges contre la metalloproteinase matricielle 9 et leurs procedes d'utilisation
US20150361182A1 (en) 2014-06-11 2015-12-17 Gilead Sciences, Inc. Methods for treating cardiovascular diseases
US10155790B2 (en) 2014-07-17 2018-12-18 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Antagonists of neurokinin B in fish reproduction
US10793614B2 (en) 2014-07-17 2020-10-06 Yissum Research Development Company of the Hebrew University ofJerusaIem Ltd. Antagonists of fish reproduction
WO2016019333A1 (fr) 2014-07-31 2016-02-04 Kinemed, Inc. Effet d'une composition phospholipidique de hdl reconstitué sur son efflux de cholestérol, et propriétés anti-inflammatoires
EP3189069B1 (fr) 2014-07-31 2024-10-23 UAB Research Foundation Peptides e-mimétiques d'apo ayant une puissance supérieure afin de dégager le taux de cholestérol plasmatique
CA2961917A1 (fr) 2014-09-22 2016-03-31 Intrinsic Lifesciences Llc Anticorps anti-hepcidine humanises et utilisations de ceux-ci
US9926375B2 (en) 2014-11-12 2018-03-27 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
AU2015346444A1 (en) 2014-11-12 2017-05-04 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
AU2016315873B2 (en) 2015-09-04 2022-08-18 Primatope Therapeutics Inc. Humanized anti-CD40 antibodies and uses thereof
US10149887B2 (en) 2015-10-23 2018-12-11 Canbas Co., Ltd. Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment
JP6877419B2 (ja) 2015-10-27 2021-05-26 ザ ユニバーシティー オブ クイーンズランド 治療の方法およびそのために有用な剤
WO2017083700A1 (fr) 2015-11-13 2017-05-18 The Board Of Regents Of The Nevada System Of Higher Education On Behalf Of The University Of Nevada, Las Vegas Thérapie basée sur une phagocytose guidée par ligand pour le traitement de la maladie d'alzheimer et d'autres maladies neurodégénératives
US20170174788A1 (en) 2015-12-17 2017-06-22 Gilead Sciences, Inc. Combination of a jak inhibitor and an mmp9 binding protein for treating inflammatory disorders
CA3019003A1 (fr) 2016-04-08 2017-10-12 Gilead Sciences, Inc. Compositions et methodes de traitement du cancer, de maladies inflammatoires et de maladies autoimmunes
WO2018071814A1 (fr) 2016-10-14 2018-04-19 The Trustees Of Columbia University In The City Of New York Procédés de traitement d'un trouble d'abus d'alcool
EP3574003A4 (fr) 2017-01-30 2020-12-02 Hudson Institute of Medical Research Méthode de traitement
WO2018213803A1 (fr) 2017-05-19 2018-11-22 Neon Therapeutics, Inc. Identification de néo-antigène immunogène
JP7366755B2 (ja) 2017-05-30 2023-10-23 ザ ボード オブ リージェンツ オブ ザ ユニヴァーシティ オブ オクラホマ 抗ダブルコルチン様キナーゼ１抗体および使用方法
KR102484433B1 (ko) 2017-11-08 2023-01-03 바이오엔테크 유에스 인크. T 세포 제조 조성물 및 방법
WO2020252208A2 (fr) 2019-06-11 2020-12-17 Myeloid Therapeutics, Inc. Compositions de recruteurs spécifiques à un macrophage et leurs méthodes d'utilisation
BR112021025050A2 (pt) 2019-06-12 2022-05-03 Biontech Us Inc Composições de neoantígeno e usos das mesmas
CA3172595A1 (fr) 2020-03-26 2021-09-30 Ronald Zimmerman Supports pharmaceutiques aptes a la reconstitution dependante du ph et leurs procedes de fabrication et d'utilisation
BR112023002733A2 (pt) 2020-08-13 2023-05-02 Biontech Us Inc Composições e métodos de fabricação de células t
JP2023549140A (ja) 2020-11-04 2023-11-22 マイエロイド・セラピューティクス，インコーポレーテッド 操作されたキメラ融合タンパク質組成物およびその使用方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1600639A (en) * 1978-05-23 1981-10-21 Kali Chemie Pharma Gmbh Medicament preparation having resorption properties and method of producing the same
US4916230A (en) * 1984-07-02 1990-04-10 Merck & Co., Inc. Process for preparing novel N-(acyloxy-alkoxy)carbonyl derivatives useful as bioreversible prodrug moieties for primary and secondary amine functions in drugs
US4946870A (en) * 1986-06-06 1990-08-07 Union Carbide Chemicals And Plastics Company Inc. Delivery systems for pharmaceutical or therapeutic actives
IT1200178B (it) * 1986-07-23 1989-01-05 Alfa Farmaceutici Spa Formulazioni galeniche a cessione programmata contenenti farmaci ad attivita' antiflogistica
US5229422A (en) * 1987-09-07 1993-07-20 Teijin Limited Extemporaneous preparation type kit of a pharmaceutical substance-containing fat emulsion
EP0351897A3 (fr) * 1988-06-17 1990-03-21 The Procter & Gamble Company Système de pénétration cutanée pour des sels d'agents pharmaceutiques à fonction amine
GB8822857D0 (en) * 1988-09-29 1988-11-02 Patralan Ltd Pharmaceutical formulations
GB8909022D0 (en) * 1989-04-20 1989-06-07 Cortecs Ltd Pharmaceutical compositions

Also Published As

Publication number Publication date
ES2073177T3 (es) 1995-08-01
KR100188642B1 (ko) 1999-06-01
CA2093206C (fr) 2002-01-29
HU211617A9 (en) 1995-12-28
HUT64215A (en) 1993-12-28
AU8731591A (en) 1992-05-20
CZ64193A3 (en) 1994-01-19
HK85296A (en) 1996-05-24
JP3276368B2 (ja) 2002-04-22
WO1992006680A1 (fr) 1992-04-30
GB9022788D0 (en) 1990-12-05
SK279845B6 (sk) 1999-04-13
NO931410L (no) 1993-04-16
FI931745A (fi) 1993-04-16
EP0553178B1 (fr) 1995-05-24
FI104408B (fi) 2000-01-31
CA2093206A1 (fr) 1992-04-20
KR930701989A (ko) 1993-09-08
RU2121344C1 (ru) 1998-11-10
SK36393A3 (en) 1993-07-07
NO931410D0 (no) 1993-04-16
BG97644A (bg) 1994-04-29
HU9301121D0 (en) 1993-07-28
FI931745A0 (fi) 1993-04-16
DE69110052T2 (de) 1995-10-05
RO114739B1 (ro) 1999-07-30
US5391377A (en) 1995-02-21
ATE122881T1 (de) 1995-06-15
NO305505B1 (no) 1999-06-14
DE69110052D1 (de) 1995-06-29
EP0553178A1 (fr) 1993-08-04
BG61383B1 (en) 1997-07-31
CZ282822B6 (cs) 1997-10-15
AU656924B2 (en) 1995-02-23
JPH06502143A (ja) 1994-03-10

Similar Documents

Publication Publication Date Title
DK0553178T3 (da) Bifasiske afgivelsesformuleringer til lipofile lægemidler
RU93048157A (ru) Фармацевтическая композиция двухфазного действия с высвобождением для липофильных лекарственных препаратов, способ ее получения, применение композиции для лечения заболеваний
Pastore et al. Transdermal patches: history, development and pharmacology
AR012854A1 (es) Una composicion de suministro de droga para la liberacion controlada de un ingrediente activo en el ambiente estomacal por un periodo de tiempoprolongado, una composicion farmaceutica que la comprende, el uso de dicha composicion en la fabricacion de un medicamento, un proceso para la preparacion
JP2009515910A5 (fr)
US20120149779A1 (en) High concentration local anesthetic formulations
DK1341527T3 (da) Farmaceutisk præparat omfattende et aktivstof dispergeret på en matrix
DE60024429D1 (de) Orale pharmazeutische zusammensetzungen, die langkettige triglyceride und lipophile tenside enthalten
IT1200178B (it) Formulazioni galeniche a cessione programmata contenenti farmaci ad attivita' antiflogistica
PT1256339E (pt) Sistema terapeutico transdermico para doenca de parkinson que induz niveis plasmaticos altos de rotigotina
NO20014718L (no) Formulering inneholdende testosteron-undekanoat og castorolje
JP2009518374A (ja) 活性薬剤、特にジクロフェナクの経皮投与
CA2534202A1 (fr) Traitement d'etats neurodegeneratifs
GEP20053455B (en) Pharmaceutical Preparations
DE60020501D1 (de) Trimetazidinhaltige Matrixtablette zur verlängerten Wirkstofffreisetzung nach oraler Gabe
JPS5576816A (en) Drug for medicinal fatty liver
PARKER Efficacy of nitroglycerin patches: fact or fancy?
Benson et al. Optimisation of Drug Delivery: 4. Transdermal Drug Delivery
DE69803772D1 (de) Oral anzuwendende feste arzneizubereitungen mit modulierter wirkstoffabgabe enthaltend nicorandil und verfahren zu deren herstellung
JP2002520269A5 (fr)
DE59908258D1 (de) Blister enthaltend ein transdermales therapeutisches system und eine einzeldosierte darreichungsform
GEP20063804B (en) Once-a-day oxycodone formulations
KR970069034A (ko) 술린닥을 활성성분으로 함유하는 소염진통제의 서방성 제제
UA86516C2 (ru) Ветеринарная биологически активная добавка липосомальной формы и способ репаративной терапии в гепатологии
TH32076B (th) รูปขนาดใช้ยางทางเภสัชกรรมสำหรับให้ทางปากซึ่งประกอบด้วยสารยับยั้งการดึงโปรตอน และสารโปรไคเนนทิค